652 related articles for article (PubMed ID: 21308717)
21. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ
Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223
[TBL] [Abstract][Full Text] [Related]
22. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
23. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
24. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
Terada N; Shimizu Y; Yoshida T; Maeno A; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O
Prostate; 2010 Feb; 70(3):252-61. PubMed ID: 19790238
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists.
Yamamoto S; Kobayashi H; Kaku T; Aikawa K; Hara T; Yamaoka M; Kanzaki N; Hasuoka A; Baba A; Ito M
Bioorg Med Chem; 2013 Jan; 21(1):70-83. PubMed ID: 23199477
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists.
Yamamoto S; Tomita N; Suzuki Y; Suzaki T; Kaku T; Hara T; Yamaoka M; Kanzaki N; Hasuoka A; Baba A; Ito M
Bioorg Med Chem; 2012 Apr; 20(7):2338-52. PubMed ID: 22391033
[TBL] [Abstract][Full Text] [Related]
27. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer.
Narayanan R; Yepuru M; Szafran AT; Szwarc M; Bohl CE; Young NL; Miller DD; Mancini MA; Dalton JT
Cancer Res; 2010 Jan; 70(2):842-51. PubMed ID: 20068182
[TBL] [Abstract][Full Text] [Related]
28. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar MD; Gleave ME
Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
[TBL] [Abstract][Full Text] [Related]
29. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
30. Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.
Kandil S; Lee KY; Davies L; Rizzo SA; Dart DA; Westwell AD
Eur J Med Chem; 2019 Apr; 167():49-60. PubMed ID: 30743097
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.
Yamamoto S; Matsunaga N; Hitaka T; Yamada M; Hara T; Miyazaki J; Santou T; Kusaka M; Yamaoka M; Kanzaki N; Furuya S; Tasaka A; Hamamura K; Ito M
Bioorg Med Chem; 2012 Jan; 20(1):422-34. PubMed ID: 22094279
[TBL] [Abstract][Full Text] [Related]
32. ARN-509: a novel antiandrogen for prostate cancer treatment.
Clegg NJ; Wongvipat J; Joseph JD; Tran C; Ouk S; Dilhas A; Chen Y; Grillot K; Bischoff ED; Cai L; Aparicio A; Dorow S; Arora V; Shao G; Qian J; Zhao H; Yang G; Cao C; Sensintaffar J; Wasielewska T; Herbert MR; Bonnefous C; Darimont B; Scher HI; Smith-Jones P; Klang M; Smith ND; De Stanchina E; Wu N; Ouerfelli O; Rix PJ; Heyman RA; Jung ME; Sawyers CL; Hager JH
Cancer Res; 2012 Mar; 72(6):1494-503. PubMed ID: 22266222
[TBL] [Abstract][Full Text] [Related]
33. Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
Poutiainen PK; Huhtala T; Jääskeläinen T; Petsalo A; Küblbeck J; Kaikkonen S; Palvimo JJ; Raunio H; Närvänen A; Peräkylä M; Juvonen RO; Honkakoski P; Laatikainen R; Pulkkinen JT
Mol Cell Endocrinol; 2014 Apr; 387(1-2):8-18. PubMed ID: 24565895
[TBL] [Abstract][Full Text] [Related]
34. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
35. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
36. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
37. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
38. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
Chen F; Knecht K; Leu C; Rutledge SJ; Scafonas A; Gambone C; Vogel R; Zhang H; Kasparcova V; Bai C; Harada S; Schmidt A; Reszka A; Freedman L
J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):247-57. PubMed ID: 15336702
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
[TBL] [Abstract][Full Text] [Related]
40. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
Serda RE; Bisoffi M; Thompson TA; Ji M; Omdahl JL; Sillerud LO
Prostate; 2008 May; 68(7):773-83. PubMed ID: 18247401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]